Why Achillion Pharmaceuticals Stock Is Jumping 15% Today

By Todd Campbell Markets Fool.com

What happened

Continue Reading Below

Shares ofAchillion Pharmaceuticals (NASDAQ: ACHN) are rallying more than 15% at 1:30 p.m. EDT Thursday after analysts at Leerink slapped a $6 price target on the stock, citing attractive potential rewards associated with the company's collaboration deal with Johnson & Johnson (NYSE: JNJ).

So what

As a refresher, Achillion Pharmaceuticals licensed its hepatitis C drug pipeline to J&Jin 2015, and ever since, J&J has been responsible for managing the two companies' research into a next-generation hepatitis C therapy that could reduce treatment duration while delivering near-100% functional cure rates.

Image source: Getty Images.

In April, J&J reported data from a phase 2 combination drug trial that includes Achllion's odalisvir. Unfortunately, those results failed to spark investor optimism. The data showed that a three-drug combination that includes Achillion's odalisvir missed its mark in genotype 3 patients, a historically hard-to-treat subset of hepatitis C patients.

Continue Reading Below

The data did show, however, that the three-drug approach delivered 100% cure rates in genotype 1 patients without cirrhosis after six or eight weeks of therapy.

However, the genotype 1 market is crowded, withGilead Sciences, AbbVie, and Merckall fighting for market share. Competition has caused prices for genotype 1 drugs to fall, shrinking the market opportunity for the indication.

Yet Leerink thinks Achillion shares could offer attractive an risk-reward proposition at current prices, especially since results from a phase 2b study involving odalisvir are on deck for later this year.

Now what

There's an important need for shorter-duration hepatitis C treatments, but six-week treatment regimens are already available to many genotype 1 patients, and more options could become available to these patients soon. Gilead Sciences' Harvoni is already used in about 40% of genotype 1 patients for six weeks, and the FDA is reviewing a new treatment from AbbVie that delivered high cure rates in as little as six weeks, too.

J&J's got the marketing muscle necessary to elbow for room in this indication, and if trials convince regulators to give it a green light, Achillion stands to benefit handsomely from milestones and royalties. However, there's a tremendous amount of risk here, and most investors are probably best off focusing on other intriguing investment ideas.

10 stocks we like better than Achillion Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Achillion Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of May 1, 2017

Todd Campbell owns shares of GILD. His clients may have positions in the companies mentioned.The Motley Fool owns shares of and recommends GILD and Johnson & Johnson. The Motley Fool has the following options: short June 2017 $70 calls on GILD. The Motley Fool has a disclosure policy.